These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 12817109)

  • 1. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
    Schrader J; Lüders S; Kulschewski A; Berger J; Zidek W; Treib J; Einhäupl K; Diener HC; Dominiak P;
    Stroke; 2003 Jul; 34(7):1699-703. PubMed ID: 12817109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
    Riegger GA; Bouzo H; Petr P; Münz J; Spacek R; Pethig H; von Behren V; George M; Arens H
    Circulation; 1999 Nov; 100(22):2224-30. PubMed ID: 10577995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P; Reismann J; Pohlmeyer H; Düsing R
    Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT; O'Kane KP; Jonker J; Roth J
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide.
    Neldam S; Forsén B;
    Drugs Aging; 2001; 18(3):225-32. PubMed ID: 11302289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS
    J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
    Reif M; White WB; Fagan TC; Oparil S; Flanagan TL; Edwards DT; Cushing DJ; Michelson EL
    Am J Cardiol; 1998 Oct; 82(8):961-5. PubMed ID: 9794352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and tolerability of candesartan cilexetil in CHF.
    Erdmann E; George M; Voet B; Belcher G; Kolb D; Hiemstra S; Pietrek M; Held P
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1 Suppl 1():31-6. PubMed ID: 11967795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
    Asmar R; Porcellati C; Dusing R
    Drugs Exp Clin Res; 2004; 30(4):153-61. PubMed ID: 15553661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing cardiovascular morbidity and mortality in the elderly.
    Trenkwalder P
    Blood Press Suppl; 2000; 1():40-3. PubMed ID: 11059636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P
    Blood Press Suppl; 2000; 1():27-30. PubMed ID: 11059633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
    Andersson OK; Neldam S
    Blood Press; 1998 Jan; 7(1):53-9. PubMed ID: 9551878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Evaluation of acute candesartan cilexetil therapy in stroke survivors.
    Kernan WN
    Stroke; 2003 Dec; 34(12):e237-8; author reply e237-8. PubMed ID: 14631078
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
    Kurokawa K; Abe K; Saruta T; Arakawa M; Kikkawa R; Ueda N; Onoyama K; Tomita K; Ogawa N
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):167-75. PubMed ID: 12563567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM; Keating GM
    Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
    Sandset EC; Bath PM; Boysen G; Jatuzis D; Kõrv J; Lüders S; Murray GD; Richter PS; Roine RO; Terént A; Thijs V; Berge E;
    Lancet; 2011 Feb; 377(9767):741-50. PubMed ID: 21316752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.